73 results about "Mirtazapine" patented technology

A reduction in the side effects of treating with an agent having combined 5HT2 / 5HT3 and alpha-2 antagonistic activity is obtained by administering an agent having selective norepinephrine reuptake inhibitory or histamine H1 agonist activity. In some embodiments, the invention provides synergistic combinations of 5HT2 / 5HT3 antagonist / alpha-2 antagonist and selective norepinephrine reuptake inhibitor or histamine H1 agonist.

Disclosed are pharmaceutical compositions comprising mirtazapine and an anticonvulsant drug. Also disclosed are methods of preventing weight gain associated with the administration of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug. Further disclosed are methods of increasing the efficacy of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug.

A reduction in the side effects of treating with an agent having combined 5HT2 / 5HT3 and alpha-2 antagonistic activity is obtained by administering an agent having histamine H1 receptor agonist activity. A combined dosage form comprising an agent having 5HT2 / 5HT3 and alpha-2 antagonistic activity and an agent having histamine H1 receptor agonist activity is presented. Some embodiments of the combined dosage form comprise an immediate release component comprising an agent having 5HT2 / 5HT3 and alpha-2 antagonistic activity and a delayed release component comprising an agent having histamine H1 receptor agonist activity. Some embodiments of the combined dosage form comprise a delayed release component comprising an agent having 5HT2 / 5HT3 and alpha-2 antagonistic activity and an immediate release component comprising an agent having histamine H1 receptor agonist activity. Methods of treatment and kits for administration are also provided.

A non-effervescent, solid dosage form containing mirtazapine, which is used to form mirtazapine pharmaceutical tablets. The dosage form contains mirtazapine, a hydrophilic component, and at least one lubricant. In some embodiments, the dosage forms contain a salivating agent. Processes for producing mirtazapine orally disintegrating tablets are also provided.

The invention discloses combination therapies and formulations of a stimulant (e.g., amphetamine) and mirtazapine and their methods of use.

The invention discloses combination therapies and formulations of a stimulant (e.g., amphetamine) and mirtazapine and their methods of use.

The invention provides a mirtazapine tablet and a preparation method thereof. The mirtazapine tablet comprises a core and a coating layer. The core comprises 20 to 45 parts of mirtazapine, 120 to 240 parts of lactose, 40 to 80 parts of sodium carboxymethyl starch, 30 to 60 parts of microcrystalline cellulose, 15 to 30 parts of low-substituted hydroxypropylcellulose, 1 to 3 parts of magnesium stearate and 1 to 3 parts of fine powder silica gel. The coating layer is a polymer coating layer containing titanium dioxide and polyethylene glycol. The preparation method comprises 1) sieving the raw and auxiliary materials of the tablet core, 2) carrying out wet granulation on the core raw materials to obtain the core, and 3) coating the tablet core to obtain the mirtazapine tablet. The dissolution of the tablet has particle size dependence, the drug release rate is stable, and side effects caused by fluctuation of the drug release rate can be avoided.

A process for producing optically active 1-methyl-3-phenylpiperazine, which is represented by the formula (11), or a salt thereof. It comprises the following steps (1) to (4) or comprises the following steps (5) to (7) and the step (4). Also provided is a process for producing optically active mirtazapine via that process.

The present application relates to compositions for use in a method of treating and / or preventing mental and behavioral disorders and / or improving mental health and cognitive functions in a subject, comprising:a) Docosahexaenoic acid (DHA) and / or the pharmaceutically acceptable derivatives and / or precursors thereof;b) Eicosapentaenoic acid (EPA) and / or the pharmaceutically acceptable derivatives and / or precursors thereof;c) γ-linolenic acid (GLA) and / or the pharmaceutically acceptable derivatives and / or precursors thereof; andat least a psychostimulant compound selected among methylphenidate HCl, atomoxetine, amphetamine, gamma-hydroxybutyrate, dextroamphetamine, sibutramine, methylenedioxymethamphetamine, and / or an anxiolytic compound selected among fluoxatine, sertraline, paroxetine, fluoroxamine, citralopram, venlafaxine, bupropion, nefazodone, and mirtazapine.The present application also relates to the method of treating and / or preventing mental and behavioral disorders and / or improving mental health and cognitive functions in a subject, comprising administering an effective amount of a composition comprising:a) Docosahexaenoic acid (DHA) and / or the pharmaceutically acceptable derivatives and / or precursors thereof;b) Eicosapentaenoic acid (EPA) and / or the pharmaceutically acceptable derivatives and / or precursors thereof;c) γ-linolenic acid (GLA) and / or the pharmaceutically acceptable derivatives and / or precursors thereof; andat least a psychostimulant compound selected among methylphenidate HCl, atomoxetine, amphetamine, gamma-hydroxybutyrate, dextroamphetamine, sibutramine, methylenedioxymethamphetamine, and / or an anxiolytic compound selected among fluoxatine, sertraline, paroxetine, fluoroxamine, citralopram, venlafaxine, bupropion, nefazodone, and mirtazapine.